Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.31 |
| ▸ | NQO2 | P16083 | 5/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940319 | 1.00 | ESR1 (0.33) | ESR1MTNR1AMTNR1BNQO2NR1I2 | |
| SCHEMBL7122203 | 0.93 | ESR1 (0.33) | ESR1 | |
| SCHEMBL5856061 | 0.92 | ESR1 (0.40) | ESR1MTNR1AMTNR1BNQO2AR | |
| SCHEMBL5854915 | 0.92 | ESR1 (0.40) | ESR1MTNR1AMTNR1BNQO2AR | |
| SCHEMBL6941157 | 0.90 | — | — | |
| SCHEMBL7084769 | 0.90 | — | — | |
| SCHEMBL7813218 | 0.89 | SIGMAR1 (0.32) | — | |
| SCHEMBL5855930 | 0.89 | ESR1 (0.40) | ESR1NR1I2AR | |
| SCHEMBL7128086 | 0.87 | MTNR1A (0.32) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5854887 | 0.87 | MTNR1A (0.32) | MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555571-B2 | Hormone inhibitor; sexual disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | ESR2, GPER1, NR5A1 | ESR1 5/4885MTNR1A 210/4885MTNR1B 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.